Latest & greatest articles for cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cancer

201. ASTRO/AUA Guideline on Hypofractionation for Localized Prostate Cancer

ASTRO/AUA Guideline on Hypofractionation for Localized Prostate Cancer Supplemental Materials for Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO, and AUA Evidence-Based Guideline - Practical Radiation Oncology Email/Username: Password: Remember me Search Terms Search within Search Share this page: Volume 8, Issue 6, Pages 354–360 Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO, and AUA (...) Evidence-Based Guideline x Scott C. Morgan Affiliations Division of Radiation Oncology, The Ottawa Hospital and University of Ottawa, Ottawa, Ontario, Canada , MD, MSc, FRCPC , x Karen Hoffman Affiliations Department of Radiation Oncology, MD Anderson Cancer Center, Houston, Texas , MD, MHSc, MPH , x D. Andrew Loblaw Affiliations Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada , MD, MSc, FRCPC, FASCO , x Mark K. Buyyounouski

American Society for Radiation Oncology2018

202. ASTRO's guideline on Palliative Radiation Therapy for Non-Small Cell Lung Cancer

ASTRO's guideline on Palliative Radiation Therapy for Non-Small Cell Lung Cancer Practical Radiation Oncology Email/Username: Password: Remember me Search Terms Search within Search Share this page: Copyright © 2018 Inc. All rights reserved. | | | | | | The content on this site is intended for health professionals. We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the . Advertisements on this site do not constitute a guarantee

American Society for Radiation Oncology2018

203. Canadian guideline on genetic screening for hereditary renal cell cancers

Canadian guideline on genetic screening for hereditary renal cell cancers CUAJ • September-October 2013 • Volume 7, Issues 9-10 © 2013 Canadian Urological Association 319 CLINICAL PRACTICE GUIDELINE 1 Division of Medical Oncology, The Ottawa Hospital Cancer Centre and the University of Ottawa, Ottawa, ON; 2 Eastern Ontario Regional Genetics Program, Children’s Hospital of Eastern Ontario and the University of Ottawa, Ottawa, ON; 3 Molecular Diagnostics, Department of Pathology, The University (...) Health Network, University of Toronto ,Toronto, ON; 4 Division of Urology, Departments of Surgical Oncology and Surgery, Princess Margaret Cancer Centre and the University Health Network, University of Toronto, Toronto, ON; 5 Division of Medical Oncology/Hematology, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON; 6 Division of Hematology/Oncology, Centre Hospitalier de l’Université de Montréal, Montreal, QC; 7 Fred A. Litwin Family Centre in Genetic Medicine, University Health

Canadian Urological Association2018

204. The Effect on Quality of Life and Body Image of Mastectomy Among Breast Cancer Survivors

The Effect on Quality of Life and Body Image of Mastectomy Among Breast Cancer Survivors 30288494 2018 11 14 14 4 2018 Oct European journal of breast health Eur J Breast Health The Effect on Quality of Life and Body Image of Mastectomy Among Breast Cancer Survivors. 205-210 10.5152/ejbh.2018.3875 The objective of the present study was to determine effect on quality of life (QoL) and body image level following mastectomy among breast cancer (BC) survivors. In this descriptive study was carried (...) out between February 2015 and December 2016 with 57 women with modified radical mastectomy and who in stage II and stage III. Data were collected using the socio-demographic and body cathexis scale, Functional Assessment of Cancer Therapy-Breast (FACT-B) to determine QoL. The study was carried out in home environment in which women lived. The average age of the women was 49.34 years (ranged 28-78 years). Most of the women had undergone mastectomy for more than 6 months.. Most of the women also

European journal of breast health2018 Full Text: Link to full Text with Trip Pro

205. The Impact of Subtype Distribution in Inflammatory Breast Cancer Outcome

The Impact of Subtype Distribution in Inflammatory Breast Cancer Outcome 30288495 2018 11 14 14 4 2018 Oct European journal of breast health Eur J Breast Health The Impact of Subtype Distribution in Inflammatory Breast Cancer Outcome. 211-217 10.5152/ejbh.2018.4170 Inflammatory breast cancer (IBC) has an unfavourable prognosis despite the advances made in the treatment of breast cancer. Our study aimed to define immunohistochemistry-based surrogate subtype distribution to determine whether (...) the breast cancer subtype accompanied survival outcome differences in IBC. Medical records of female breast cancer patients with non-metastatic inflammatory breast cancer admitted to our clinic between March 2000 and December 2015 were retrospectively reviewed. Patient demographics, clinical and pathological feature of the primary tumour, adjuvant treatment options and survival data were analysed. Intrinsic breast cancer subtypes were defined according to ER, PR, HER-2 and ki-67 status. We identified 129

European journal of breast health2018 Full Text: Link to full Text with Trip Pro

206. QOL Evaluation of Nab-Paclitaxel and Docetaxel for Early Breast Cancer

QOL Evaluation of Nab-Paclitaxel and Docetaxel for Early Breast Cancer 30288492 2018 11 14 14 4 2018 Oct European journal of breast health Eur J Breast Health QOL Evaluation of Nab-Paclitaxel and Docetaxel for Early Breast Cancer. 194-198 10.5152/ejbh.2018.4174 A previous randomized phase II study showed that neoadjuvant nab-paclitaxel (nab-PTX) 100 mg/m 2 ) was effective and well-tolerated in patients with HER2-negative early-stage breast cancer, compared with docetaxel (DTX). We evaluated (...) patient outcomes in terms of the Functional Assessment of Cancer Therapy-Breast (FACT-B), as a measure of health-related quality of life (HRQoL). Stage I-III HER2-negative breast cancer patients from the previous study were included. They received either four cycles of nab-PTX (100 mg/m 2 days 1/8/15) every 4 weeks, or DTX (75 mg/m 2 day 1) every 3 weeks, both followed by four cycles of 5-fluorouracil/epirubicin/cyclophosphamide (FEC). Patients completed a health-related quality-of-life questionnaire

European journal of breast health2018 Full Text: Link to full Text with Trip Pro

207. Risk-Reducing Options for Women with a Hereditary Breast Cancer Predisposition

Risk-Reducing Options for Women with a Hereditary Breast Cancer Predisposition 30288491 2018 11 14 14 4 2018 Oct European journal of breast health Eur J Breast Health Risk-Reducing Options for Women with a Hereditary Breast Cancer Predisposition. 189-193 10.5152/ejbh.2018.4324 Genetic testing is now widely utilized to identify women with a hereditary predisposition for breast cancer. Women who carry mutations that increase breast cancer risk may consider three options to reduce risk: screening (...) , chemoprevention, and prophylactic surgery. Yet, no randomized trials have specifically assessed the efficacy of these options in mutation carriers. In many developed countries, mammography is regarded as the optimal means of screening for breast cancer in the general population. However, breast MRI is a more sensitive screening tool, and for mutation carriers, any breast cancer screening strategy should incorporate screening with MRI. In randomized trials of women at high risk for developing breast cancer

European journal of breast health2018 Full Text: Link to full Text with Trip Pro

208. The Significance of Extent of Extracapsular Extension in Patients with T1-2 and N1 Breast Cancer

The Significance of Extent of Extracapsular Extension in Patients with T1-2 and N1 Breast Cancer 30288496 2018 11 14 14 4 2018 Oct European journal of breast health Eur J Breast Health The Significance of Extent of Extracapsular Extension in Patients with T1-2 and N1 Breast Cancer. 218-224 10.5152/ejbh.2018.4038 The prognostic importance of extracapsular extension (ECE) in breast cancer is not yet clear, especially in patients with pathological T1-2 and N1 (pT1-2N1) disease. We aimed (...) to investigate whether the extent of ECE was an independent prognostic factor for survival outcomes in patients with pT1-2N1 breast cancer. A total number of 131 patients with pT1-2N1 breast cancer treated between 2009 and 2015 were retrospectively evaluated. A single pathologist re-analyzed the histologic examples of all cases. The extent of ECE was graded from 0 to 4. There was a significant correlation between the number of lymph nodes involved and ECE grade (p=0.004). According to the univariate analysis

European journal of breast health2018 Full Text: Link to full Text with Trip Pro

209. Evaluation of Breast Cancer (BC) Awareness among Female University Students in Zarqa University, Jordan

Evaluation of Breast Cancer (BC) Awareness among Female University Students in Zarqa University, Jordan 30288493 2018 11 14 14 4 2018 Oct European journal of breast health Eur J Breast Health Evaluation of Breast Cancer (BC) Awareness among Female University Students in Zarqa University, Jordan. 199-204 10.5152/ejbh.2018.4048 The purposes of this study were to assess the level of Breast Cancer (BC) awareness of Jordanian female university students, measure their attitudes toward BC treatment (...) Sciences, Zarqa, Jordan. eng Journal Article 2018 10 01 Turkey Eur J Breast Health 101709357 Awareness attitudes breast cancer knowledge Conflict of Interest: The author have no conflicts of interest to declare. 2018 03 10 2018 04 19 2018 10 6 6 0 2018 10 6 6 0 2018 10 6 6 1 epublish 30288493 10.5152/ejbh.2018.4048 ejbh-14-4-199 PMC6170026 Asian Pac J Cancer Prev. ;18(3):847-856 28441797 Asian Pac J Cancer Prev. 2013;14(7):4307-12 23991994 Breast Cancer Res. 2004;6(6):229-39 15535852 J Basic Clin Pharm

European journal of breast health2018 Full Text: Link to full Text with Trip Pro

210. Prostate cancer

Prostate cancer Prostate cancer - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Prostate cancer Last reviewed: September 2018 Last updated: September 2018 Important updates Safety concerns prompt EMA to restrict the use of radium-223 in metastatic prostate cancer New restrictions have been placed on the use of radium-223 for the treatment of metastatic prostate cancer following a safety review by the European (...) Medicines Agency (EMA). The review concluded that the use of radium-223 is associated with an increased risk of fractures and a possible increased risk of death. The EMA has imposed the following new restrictions on the use of radium-223: Restrict use to patients who have received two prior treatments for metastatic prostate cancer, or who cannot receive other treatments Do not use with abiraterone and prednisolone (this combination is contraindicated) Do not use with other systemic cancer therapies

BMJ Best Practice2018

211. Development, Evaluation, and Implementation of a Pan-African Cancer Research Network: Men of African Descent and Carcinoma of the Prostate

Development, Evaluation, and Implementation of a Pan-African Cancer Research Network: Men of African Descent and Carcinoma of the Prostate 30260755 2018 12 07 2378-9506 4 2018 Sep Journal of global oncology J Glob Oncol Development, Evaluation, and Implementation of a Pan-African Cancer Research Network: Men of African Descent and Carcinoma of the Prostate. 1-14 10.1200/JGO.18.00063 Cancer of the prostate (CaP) is the leading cancer among men in sub-Saharan Africa (SSA). A substantial (...) proportion of these men with CaP are diagnosed at late (usually incurable) stages, yet little is known about the etiology of CaP in SSA. We established the Men of African Descent and Carcinoma of the Prostate Network, which includes seven SSA centers partnering with five US centers to study the genetics and epidemiology of CaP in SSA. We developed common data elements and instruments, regulatory infrastructure, and biosample collection, processing, and shipping protocols. We tested this infrastructure

Journal of global oncology2018 Full Text: Link to full Text with Trip Pro

212. Treating EGFR-Mutated Oncogene-Addicted Advanced Non–Small-Cell Lung Cancer in the Era of Economic Crisis in Greece: Challenges and Opportunities

Treating EGFR-Mutated Oncogene-Addicted Advanced Non–Small-Cell Lung Cancer in the Era of Economic Crisis in Greece: Challenges and Opportunities 30260753 2018 12 07 2378-9506 4 2018 Sep Journal of global oncology J Glob Oncol Treating EGFR-Mutated Oncogene-Addicted Advanced Non-Small-Cell Lung Cancer in the Era of Economic Crisis in Greece: Challenges and Opportunities. 1-12 10.1200/JGO.18.00115 Because of the profound financial crisis that commenced in Greece in 2010, severe cuts in health (...) care spending and other restriction measures led to significant delays in the reimbursement of novel antineoplastic agents. In 2011, the Hellenic Society of Medical Oncology initiated a program of early access to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for the treatment of patients with advanced, EGFR-mutant non-small-cell lung cancer (NSCLC). We evaluated treatment patterns and clinical outcomes in patients with EGFR-mutant or wild-type disease treated at a large center

Journal of global oncology2018 Full Text: Link to full Text with Trip Pro

213. Effective Project Management of a Pan-African Cancer Research Network: Men of African Descent and Carcinoma of the Prostate (MADCaP)

Effective Project Management of a Pan-African Cancer Research Network: Men of African Descent and Carcinoma of the Prostate (MADCaP) 30260756 2018 12 07 2378-9506 4 2018 Sep Journal of global oncology J Glob Oncol Effective Project Management of a Pan-African Cancer Research Network: Men of African Descent and Carcinoma of the Prostate (MADCaP). 1-12 10.1200/JGO.18.00062 Health research in low- and middle-income countries can generate novel scientific knowledge and improve clinical care (...) , fostering population health improvements to prevent premature death. Project management is a critical part of the success of this research, applying knowledge, skills, tools, and techniques to accomplish required goals. Here, we describe the development and implementation of tools to support a multifaceted study of prostate cancer in Africa, focusing on building strategic and operational capacity. Applying a learning organizational framework, we developed and implemented a project management toolkit

Journal of global oncology2018 Full Text: Link to full Text with Trip Pro

214. Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy: Treatment Patterns From the PROXIMA Prospective Registry

Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy: Treatment Patterns From the PROXIMA Prospective Registry 30260754 2018 12 07 2378-9506 4 2018 Sep Journal of global oncology J Glob Oncol Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy: Treatment Patterns From the PROXIMA Prospective Registry. 1-12 10.1200/JGO.18.00009 There is a major clinical need to devise an optimal treatment sequence (...) for the multiple therapy options available for patients with metastatic castration-resistant prostate cancer (mCRPC). In the absence of prospective clinical trials, sequencing information can be derived from large, real-world registry studies. PROXIMA (Treatment Patterns in Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy) is a large, global, prospective registry study evaluating real-world treatment patterns of patients with mCRPC who

Journal of global oncology2018 Full Text: Link to full Text with Trip Pro

215. Reported use of reporting guidelines among JNCI: Journal of the National Cancer Institute authors, editorial outcomes, and reviewer ratings related to adherence to guidelines and clarity of presentation

Reported use of reporting guidelines among JNCI: Journal of the National Cancer Institute authors, editorial outcomes, and reviewer ratings related to adherence to guidelines and clarity of presentation 30275983 2018 11 14 2058-8615 3 2018 Research integrity and peer review Res Integr Peer Rev Reported use of reporting guidelines among JNCI: Journal of the National Cancer Institute authors, editorial outcomes, and reviewer ratings related to adherence to guidelines and clarity of presentation (...) . 7 10.1186/s41073-018-0052-4 Associations were examined between author-reported uses of reporting guidelines to prepare JNCI: Journal of the National Cancer Institute ( JNCI ) submissions, editorial decisions, and reviewer ratings for adherence to reporting guidelines and clarity of presentation. At submission, authors were asked if they used reporting guidelines to prepare their manuscript and, if so, which one(s). Reviewers rated adherence to reporting guidelines and clarity of presentation

Research integrity and peer review2018 Full Text: Link to full Text with Trip Pro

216. Association between contemporary hormonal contraception and ovarian cancer in women of reproductive age in Denmark: prospective, nationwide cohort study.

Association between contemporary hormonal contraception and ovarian cancer in women of reproductive age in Denmark: prospective, nationwide cohort study. OBJECTIVES: To investigate the association between contemporary combined hormonal contraceptives (including progestogen types in combined preparations and all progestogen-only products) and overall and specific types of ovarian cancer. DESIGN: Prospective, nationwide cohort study. SETTING: Denmark, 1995-2014. PARTICIPANTS: All women aged 15-49 (...) years during 1995-2014 were eligible. Women were excluded if they immigrated after 1995, had cancer (except non-melanoma skin cancer), had venous thrombosis, or were treated for infertility before entry (final study population included 1 879 227 women). Women were categorised as never users (no record of being dispensed hormonal contraception), current or recent users (≤1 year after stopping use), or former users (>1 year after stopping use) of different hormonal contraceptives. MAIN OUTCOME

BMJ2018

217. Can nut consumption improve colon cancer survival?

Can nut consumption improve colon cancer survival? 30363796 2018 11 14 2415-1289 3 2018 Translational gastroenterology and hepatology Transl Gastroenterol Hepatol Can nut consumption improve colon cancer survival? 73 10.21037/tgh.2018.09.14 Aune Dagfinn D Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK. Department of Nutrition, Bjørknes University College, Oslo, Norway. Department of Endocrinology, Morbid Obesity and Preventive Medicine

Translational gastroenterology and hepatology2018 Full Text: Link to full Text with Trip Pro

218. Prevalence of Variant Reclassification Following Hereditary Cancer Genetic Testing.

Prevalence of Variant Reclassification Following Hereditary Cancer Genetic Testing. Importance: Variant reclassification is an important component of hereditary cancer genetic testing; however, there are few published data quantifying the prevalence of reclassification. Objective: Retrospective cohort study of individuals who had genetic testing from 2006 through 2016 at a single commercial laboratory. Design, Setting, and Participants: A retrospective cohort of individuals who had genetic (...) testing between 2006 and 2016 at a single commercial laboratory was assessed. Variants were classified as benign, likely benign, variant of uncertain significance, likely pathogenic, or pathogenic. Retrospective chart reviews were conducted for patients from the University of Texas Southwestern (UTSW) Medical Center. Exposures: Hereditary cancer genetic testing. Main Outcomes and Measures: Frequency of and time to amended reports; frequency and types of variant reclassification. Results: From 2006

JAMA2018

219. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.

Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. BACKGROUND: Standard first-line therapy for metastatic, squamous non-small-cell lung cancer (NSCLC) is platinum-based chemotherapy or pembrolizumab (for patients with programmed death ligand 1 [PD-L1] expression on ≥50% of tumor cells). More recently, pembrolizumab plus chemotherapy was shown to significantly prolong overall survival among patients with nonsquamous NSCLC. METHODS: In this double-blind, phase 3 trial, we (...) randomly assigned, in a 1:1 ratio, 559 patients with untreated metastatic, squamous NSCLC to receive 200 mg of pembrolizumab or saline placebo for up to 35 cycles; all the patients also received carboplatin and either paclitaxel or nanoparticle albumin-bound [nab]-paclitaxel for the first 4 cycles. Primary end points were overall survival and progression-free survival. RESULTS: After a median follow-up of 7.8 months, the median overall survival was 15.9 months (95% confidence interval [CI], 13.2

NEJM2018

220. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. BACKGROUND: Enhancing tumor-specific T-cell immunity by inhibiting programmed death ligand 1 (PD-L1)-programmed death 1 (PD-1) signaling has shown promise in the treatment of extensive-stage small-cell lung cancer. Combining checkpoint inhibition with cytotoxic chemotherapy may have a synergistic effect and improve efficacy. METHODS: We conducted this double-blind, placebo-controlled, phase 3 trial to evaluate (...) atezolizumab plus carboplatin and etoposide in patients with extensive-stage small-cell lung cancer who had not previously received treatment. Patients were randomly assigned in a 1:1 ratio to receive carboplatin and etoposide with either atezolizumab or placebo for four 21-day cycles (induction phase), followed by a maintenance phase during which they received either atezolizumab or placebo (according to the previous random assignment) until they had unacceptable toxic effects, disease progression

NEJM2018